A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

Penny A. Dacks, Joshua J. Armstrong, Stephen K. Brannan, Aaron J. Carman, Allan M. Green, M. Sue Kirkman, Lawrence R. Krakoff, Lewis H. Kuller, Lenore J. Launer, Simon Lovestone, Elizabeth Merikle, Peter J. Neumann, Kenneth Rockwood, Diana W. Shineman, Richard G. Stefanacci, Priscilla Velentgas, Anand Viswanathan, Rachel Whitmer, Jeff D. Williamson, Howard M. Fillit

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.

Original languageEnglish (US)
Article number200
JournalAlzheimer's Research and Therapy
Volume8
Issue number1
DOIs
StatePublished - Aug 20 2016
Externally publishedYes

Fingerprint

Comparative Effectiveness Research
Dementia
Brain
Cholinergic Antagonists
Drug Discovery
Benzodiazepines
Atrial Fibrillation
Cholinergic Agents
Alzheimer Disease
Chronic Disease
Therapeutics
Pathology
Hypertension
Health
Research
Cognitive Dysfunction

Keywords

  • Alzheimer's
  • Cognitive aging
  • Cognitive decline
  • Comorbidity
  • Comparative effectiveness
  • Dementia
  • Diabetes
  • Hypertension
  • Prevention
  • Repurposing

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. / Dacks, Penny A.; Armstrong, Joshua J.; Brannan, Stephen K.; Carman, Aaron J.; Green, Allan M.; Kirkman, M. Sue; Krakoff, Lawrence R.; Kuller, Lewis H.; Launer, Lenore J.; Lovestone, Simon; Merikle, Elizabeth; Neumann, Peter J.; Rockwood, Kenneth; Shineman, Diana W.; Stefanacci, Richard G.; Velentgas, Priscilla; Viswanathan, Anand; Whitmer, Rachel; Williamson, Jeff D.; Fillit, Howard M.

In: Alzheimer's Research and Therapy, Vol. 8, No. 1, 200, 20.08.2016.

Research output: Contribution to journalReview article

Dacks, PA, Armstrong, JJ, Brannan, SK, Carman, AJ, Green, AM, Kirkman, MS, Krakoff, LR, Kuller, LH, Launer, LJ, Lovestone, S, Merikle, E, Neumann, PJ, Rockwood, K, Shineman, DW, Stefanacci, RG, Velentgas, P, Viswanathan, A, Whitmer, R, Williamson, JD & Fillit, HM 2016, 'A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline', Alzheimer's Research and Therapy, vol. 8, no. 1, 200. https://doi.org/10.1186/s13195-016-0200-3
Dacks, Penny A. ; Armstrong, Joshua J. ; Brannan, Stephen K. ; Carman, Aaron J. ; Green, Allan M. ; Kirkman, M. Sue ; Krakoff, Lawrence R. ; Kuller, Lewis H. ; Launer, Lenore J. ; Lovestone, Simon ; Merikle, Elizabeth ; Neumann, Peter J. ; Rockwood, Kenneth ; Shineman, Diana W. ; Stefanacci, Richard G. ; Velentgas, Priscilla ; Viswanathan, Anand ; Whitmer, Rachel ; Williamson, Jeff D. ; Fillit, Howard M. / A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. In: Alzheimer's Research and Therapy. 2016 ; Vol. 8, No. 1.
@article{ad3f8bc2aa3f4e8cbaa5a889adb56a24,
title = "A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline",
abstract = "Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.",
keywords = "Alzheimer's, Cognitive aging, Cognitive decline, Comorbidity, Comparative effectiveness, Dementia, Diabetes, Hypertension, Prevention, Repurposing",
author = "Dacks, {Penny A.} and Armstrong, {Joshua J.} and Brannan, {Stephen K.} and Carman, {Aaron J.} and Green, {Allan M.} and Kirkman, {M. Sue} and Krakoff, {Lawrence R.} and Kuller, {Lewis H.} and Launer, {Lenore J.} and Simon Lovestone and Elizabeth Merikle and Neumann, {Peter J.} and Kenneth Rockwood and Shineman, {Diana W.} and Stefanacci, {Richard G.} and Priscilla Velentgas and Anand Viswanathan and Rachel Whitmer and Williamson, {Jeff D.} and Fillit, {Howard M.}",
year = "2016",
month = "8",
day = "20",
doi = "10.1186/s13195-016-0200-3",
language = "English (US)",
volume = "8",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

AU - Dacks, Penny A.

AU - Armstrong, Joshua J.

AU - Brannan, Stephen K.

AU - Carman, Aaron J.

AU - Green, Allan M.

AU - Kirkman, M. Sue

AU - Krakoff, Lawrence R.

AU - Kuller, Lewis H.

AU - Launer, Lenore J.

AU - Lovestone, Simon

AU - Merikle, Elizabeth

AU - Neumann, Peter J.

AU - Rockwood, Kenneth

AU - Shineman, Diana W.

AU - Stefanacci, Richard G.

AU - Velentgas, Priscilla

AU - Viswanathan, Anand

AU - Whitmer, Rachel

AU - Williamson, Jeff D.

AU - Fillit, Howard M.

PY - 2016/8/20

Y1 - 2016/8/20

N2 - Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.

AB - Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.

KW - Alzheimer's

KW - Cognitive aging

KW - Cognitive decline

KW - Comorbidity

KW - Comparative effectiveness

KW - Dementia

KW - Diabetes

KW - Hypertension

KW - Prevention

KW - Repurposing

UR - http://www.scopus.com/inward/record.url?scp=84982290289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982290289&partnerID=8YFLogxK

U2 - 10.1186/s13195-016-0200-3

DO - 10.1186/s13195-016-0200-3

M3 - Review article

C2 - 27543171

AN - SCOPUS:84982290289

VL - 8

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 1

M1 - 200

ER -